RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

Proximal phalanx injection for trigger finger: randomized controlled trial.

Trigger finger is one of the most common upper extremity problems in the outpatient department. Conservative treatment is the mainstay for management of trigger digits especially steroid injection with highly satisfactory outcome and minimal complication. Conventional injection technique (CI) that approaches flexor tendon sheath over metacarpal head directly causes pain for most patients. The proximal phalanx injection technique (P1I) at palmar surface of midproximal phalanx is simple and less painful for the patients. We compared pain result and effectiveness between these two methods. Forty patients with primary trigger fingers were placed in a prospective randomized study to receive steroid injection with either the CI or P1I techniques. Demographic data were recorded. Immediately after the injection, pain score was recorded for each patient using the pain visual analog scale. The patients were followed every month for three months to determine recurrent symptoms. Student's t-test, chi-square and Fisher's exact test were used for data analysis. The mean pain VAS scores immediately post-injection were 7.3 ± 1.3 and 3.2 ± 2.2 in the CI and P1I techniques, respectively. The P1I technique group had a significantly lower pain score than CI technique group (p < 0.001). The recurrence rate was 15% in the CI technique when compared to 25% in the P1I technique which was not significant (p = 0.685). We concluded that the P1I technique is less painful than the CI technique without any significant difference in recurrence rate between the two groups at three months follow-up.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app